Derijks LJJ - Search Results

1

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study.

Sivridaş M, Creemers RH, Wong DR, Boekema PJ, Römkens TEH, Gilissen LPL, van Bodegraven AA, Loeff FC, Rispens T, Derijks LJJ. Sivridaş M, et al. Among authors: derijks ljj. Pharmaceutics. 2023 Mar 17;15(3):972. doi: 10.3390/pharmaceutics15030972. Pharmaceutics. 2023. PMID: 36986833 Free PMC article.

2

6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.

Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, Mulder CJ. Derijks LJ, et al. Eur J Gastroenterol Hepatol. 2003 Jan;15(1):63-7. doi: 10.1097/00042737-200301000-00011. Eur J Gastroenterol Hepatol. 2003. PMID: 12544696 Clinical Trial.

3

Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.

Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM. Derijks LJ, et al. Ther Drug Monit. 2004 Jun;26(3):311-8. doi: 10.1097/00007691-200406000-00016. Ther Drug Monit. 2004. PMID: 15167634 Clinical Trial.

4

Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients.

Gilissen LP, Derijks LJ, Bos LP, Verhoeven HM, Bus PJ, Hooymans PM, Engels LG. Gilissen LP, et al. Eur J Gastroenterol Hepatol. 2004 Jul;16(7):705-10. doi: 10.1097/01.meg.0000108333.52416.63. Eur J Gastroenterol Hepatol. 2004. PMID: 15201586

5

Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease.

Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, van Deventer SJ, Hommes DW, Hooymans PM. Derijks LJ, et al. Ther Drug Monit. 2006 Feb;28(1):45-50. doi: 10.1097/01.ftd.0000179839.71138.6d. Ther Drug Monit. 2006. PMID: 16418693 Clinical Trial.

6

6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?

Derijks LJ, Gilissen LP, de Boer NK, Mulder CJ. Derijks LJ, et al. J Hepatol. 2006 Apr;44(4):821-2. doi: 10.1016/j.jhep.2005.11.049. Epub 2006 Jan 24. J Hepatol. 2006. PMID: 16487623 No abstract available.

7

The role of xanthine oxidase in thiopurine metabolism: a case report.

Wong DR, Derijks LJ, den Dulk MO, Gemmeke EH, Hooymans PM. Wong DR, et al. Ther Drug Monit. 2007 Dec;29(6):845-8. doi: 10.1097/FTD.0b013e31815bf4dc. Ther Drug Monit. 2007. PMID: 18043486

8

Pharmacogenetics of thiopurines in inflammatory bowel disease.

Derijks LJ, Wong DR. Derijks LJ, et al. Curr Pharm Des. 2010;16(2):145-54. doi: 10.2174/138161210790112773. Curr Pharm Des. 2010. PMID: 20205660 Review.

9

Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.

Warman A, Straathof JW, Derijks LJ. Warman A, et al. Eur J Gastroenterol Hepatol. 2015 Mar;27(3):242-8. doi: 10.1097/MEG.0000000000000279. Eur J Gastroenterol Hepatol. 2015. PMID: 25569569

10

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.

Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team. Coenen MJ, et al. Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002. Epub 2015 Jun 11. Gastroenterology. 2015. PMID: 26072396 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page